tetano
Editor, Senior Moderator
Nat Rev Immunol
. 2021 Dec 15.
doi: 10.1038/s41577-021-00665-1. Online ahead of print.
The state of complement in COVID-19
Behdad Afzali[SUP] 1 [/SUP], Marina Noris[SUP] 2 3 [/SUP], Bart N Lambrecht[SUP] 4 5 6 [/SUP], Claudia Kemper[SUP] 7 8 [/SUP]
Affiliations
Abstract
Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.
. 2021 Dec 15.
doi: 10.1038/s41577-021-00665-1. Online ahead of print.
The state of complement in COVID-19
Behdad Afzali[SUP] 1 [/SUP], Marina Noris[SUP] 2 3 [/SUP], Bart N Lambrecht[SUP] 4 5 6 [/SUP], Claudia Kemper[SUP] 7 8 [/SUP]
Affiliations
- PMID: 34912108
- DOI: 10.1038/s41577-021-00665-1
Abstract
Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.